Invention Grant
- Patent Title: Bispecific antibodies to ROR1 and CD3
-
Application No.: US16628404Application Date: 2018-07-05
-
Publication No.: US11306142B2Publication Date: 2022-04-19
- Inventor: Amit Nathwani , Satyen Gohil , Marco Della Peruta
- Applicant: UCL Business LTD
- Applicant Address: GB London
- Assignee: UCL Business LTD
- Current Assignee: UCL Business LTD
- Current Assignee Address: GB London
- Agency: Choate, Hall & Stewart LLP
- Agent Brenda Herschbach Jarrell; Melissa M. Adams
- Priority: GB1710838 20170705
- International Application: PCT/GB2018/051916 WO 20180705
- International Announcement: WO2019/008379 WO 20190110
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61P35/00
Abstract:
There is described bispecific antibodies which selectively bind to Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1) and the CD3 subunit of the T-Cell Receptor (TCR), their production and their use. Also described is the use of the bispecific antibodies in the treatment of cancer.
Public/Granted literature
- US20200157218A1 BISPECIFIC ANTIBODIES TO ROR1 AND CD3 Public/Granted day:2020-05-21
Information query
